Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

Study of Real-World Outcomes in Adults With CIDP After Standard Treatment

Age
18 years or above
Gender
All
Phase
N/A
Participants needed
200
Find a study site near you

Study Overview

This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. The study is expected to last two years. Enrollment is expected to continue for one year. Depending on when the participant is enrolled, a participant can be followed for between one and two years, through the end of study, approximately two years after the study starts.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Neurologist-confirmed diagnosis of CIDP found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed

  • Active use of at least one of the following CIDP treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment

    • immunoglobulin
    • corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day
    • plasma exchange
    • efgartigimod alfa
    • azathioprine
    • mycophenolate mofetil
    • cyclosporine
    • rituximab
    • methotrexate
  • Signed informed consent
  • Residual impairment, disability, or neurological deficits at enrollment, as defined by a raw I-RODS score of 44 or below

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Evidence of participation in any interventional clinical trial with an investigational drug at the time of enrollment
  • Hyperreflexia (increased reflexes) recorded in the medical record during a neurological exam the year before enrollment and after CIDP diagnosis
  • Aged under 18 at the time of enrollment

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

The purpose of this research study is to describe treatment outcomes in adults in the United States who have chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) and who still have ongoing problems (such as disability or nerve-related symptoms) after at least three months of standard CIDP treatment.

Participants will not receive a study treatment as part of this study. The study team will collect information from participants’ medical records about their CIDP and the treatments they are using.

Who can participate:
Adults with CIDP may be able to participate if they:

  • Are 18 years or older
  • Have a neurologist-confirmed CIDP diagnosis in their medical record
  • Are currently using at least one standard CIDP treatment and have been using it for three months or longer
  • Still have disability or nerve-related problems at the time they join the study

Study timeline and visits:
Participation lasts between 1 and 2 years, depending on when a person joins the study. The study is expected to last about 2 years in total.

Updated on 23 Jul 2026. Study ID: NCT06968975

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.